ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2494

Complement mRNA Expression in Patients with ANCA-associated Glomerulonephritis

Salem Almaani1, Arnon Arazi2, Huijuan Song3, Pearlly Yan3, Estela Puchulu-Campanella3, Hubao Wang3, Lynn Fussner3, Samir Parikh3 and Brad Rovin3, 1Ohio State University Medical Center, Columbus, OH, 2Broad Institute of MIT and Harvard, Melrose, MA, 3Ohio State University, Columbus, OH

Meeting: ACR Convergence 2023

Keywords: ANCA associated vasculitis, complement, Gene Expression

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: Abstracts: Vasculitis – ANCA-Associated II

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: The role of complement in patients with ANCA-associated vasculitis (AAV) has been increasingly appreciated and led to the use of complement system antagonists as a therapeutic strategy. However, it is unclear whether complement system activation occurs in affected organs such as the kidneys. This study aimed to characterize complement gene expression in patients with AAV with renal involvement (AAGN).

Methods: Whole-tissue RNA-sequencing was performed on kidney biopsy samples of 23 patients with AAGN, and 5 healthy kidney donors. After quality control, differential expression (DGE) analysis was performed using generalized linear models correcting for number of genes and batch effects. This abstract describes mRNA expression of 42 complement system proteins, receptors, and regulators. For this analysis, differential expression was considered statistically if the FDR-corrected p-value < 0.05, and the absolute value of log2 fold change between groups was > 0.6 (|log2FC| > 0.6).

Results: Patients’ clinical and demographic characteristics are depicted in Table 1. Most patients were female (13/23), White (21/23), and had a median age of 58 years. Most patients had c-ANCAs and a granulomatosis with polyangiitis phenotype. DGE analysis (Figure 1) revealed increased abundance of mRNA coding for proteins participating in the classical (C1q, C1r, C1s, C2, C4B), alternative (CFB, CFD), and common (C3, C7) complement pathways. In addition, there was an increase in abundance of the anaphylatoxin receptors (C3AR, C5AR). mRNA abundance of complement regulators (CFH, CD55, CD46, CR1) were not different compared to controls except for CR2 which was decreased in patients with AAGN.

Conclusion: Analysis of mRNA expression in kidneys of patients with AAGN reveals increased abundance of members of the classical and alternative complement pathways, anaphylatoxin receptors, without a concomitant increase in mRNA expression of complement regulatory proteins. Along with our previous finding of increased complement activation products in urine of patients with active AAGN, these data strongly suggest intra-renal complement system activation in patients with AAGN.

Supporting image 1

Table 1. Patient and Disease Characteristics

Supporting image 2

Complement mRNA expression of AAGN vs controls


Disclosures: S. Almaani: Amgen, 2, Aurinia, 2, Chemocentryx, 2, Kezar, 2, Otsuka, 2; A. Arazi: None; H. Song: None; P. Yan: None; E. Puchulu-Campanella: None; H. Wang: None; L. Fussner: Amgen, 2; S. Parikh: Alexion, 2, Aurinia, 2, Bristol-Myers Squibb(BMS), 2, Kezar life sciences, 2; B. Rovin: AstraZeneca, 2, 5, Aurinia, 2, 5, Biogen, 2, F. Hoffmann-La Roche Ltd, 2, Genentech, 2, GlaxoSmithKlein(GSK), 2, Novartis, 2.

To cite this abstract in AMA style:

Almaani S, Arazi A, Song H, Yan P, Puchulu-Campanella E, Wang H, Fussner L, Parikh S, Rovin B. Complement mRNA Expression in Patients with ANCA-associated Glomerulonephritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/complement-mrna-expression-in-patients-with-anca-associated-glomerulonephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/complement-mrna-expression-in-patients-with-anca-associated-glomerulonephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology